A screening programme for gestational diabetes mellitus (GDM) in a tertiary centre in Delhi compares two tests: Test A (75-g OGTT) and Test B (random blood glucose). Test A has 90% sensitivity and 88% specificity. Test B has 70% sensitivity and 95% specificity. Among pregnant women attending the antenatal clinic (GDM prevalence ~20%), which single finding best distinguishes the diagnostic value of these two tests?

Explanation

## Comparing GDM Screening Tests in a High-Prevalence Setting ### Clinical Context - **Population:** Pregnant women in Delhi (high-risk region) - **GDM prevalence:** 20% (relatively high compared to global average of 6–7%) - **Test A (75-g OGTT):** Sensitivity 90%, Specificity 88% - **Test B (Random glucose):** Sensitivity 70%, Specificity 95% ### Calculating Negative Predictive Value (NPV) Using: $NPV = \frac{Specificity \times (1-Prevalence)}{Specificity \times (1-Prevalence) + (1-Sensitivity) \times Prevalence}$ **Test A (Sensitivity 90%, Specificity 88%):** $$NPV_A = \frac{0.88 \times 0.80}{0.88 \times 0.80 + 0.10 \times 0.20} = \frac{0.704}{0.704 + 0.02} = \frac{0.704}{0.724} \approx 97.2\%$$ **Test B (Sensitivity 70%, Specificity 95%):** $$NPV_B = \frac{0.95 \times 0.80}{0.95 \times 0.80 + 0.30 \times 0.20} = \frac{0.76}{0.76 + 0.06} = \frac{0.76}{0.82} \approx 92.7\%$$ ### Calculating Positive Predictive Value (PPV) Using: $PPV = \frac{Sensitivity \times Prevalence}{Sensitivity \times Prevalence + (1-Specificity) \times (1-Prevalence)}$ **Test A:** $$PPV_A = \frac{0.90 \times 0.20}{0.90 \times 0.20 + 0.12 \times 0.80} = \frac{0.18}{0.18 + 0.096} = \frac{0.18}{0.276} \approx 65.2\%$$ **Test B:** $$PPV_B = \frac{0.70 \times 0.20}{0.70 \times 0.20 + 0.05 \times 0.80} = \frac{0.14}{0.14 + 0.04} = \frac{0.14}{0.18} \approx 77.8\%$$ ### Key Discriminating Feature: NPV **High-Yield:** In a **high-prevalence setting** (20% GDM prevalence), **sensitivity becomes the dominant determinant of NPV**. Test A's higher sensitivity (90% vs 70%) translates to a substantially higher NPV (97.2% vs 92.7%). **Key Point:** Test A's NPV of 97.2% means that a **negative result reliably excludes GDM** in 97 out of 100 cases. Test B's NPV of 92.7% leaves a 7.3% false-negative rate — clinically significant when screening for a condition with maternal and fetal consequences. ### Comparison Table | Feature | Test A (OGTT) | Test B (Random glucose) | Winner | |---------|---------------|-------------------------|--------| | **Sensitivity** | 90% | 70% | Test A | | **Specificity** | 88% | 95% | Test B | | **PPV (at 20% prev.)** | ~65% | ~78% | Test B | | **NPV (at 20% prev.)** | **~97%** | **~93%** | **Test A** | | **Clinical role** | **Screening/Rule-out** | Confirmation | **Test A for exclusion** | ### Clinical Pearl: Screening vs. Confirmation in High Prevalence **Mnemonic:** **"High Sens = High NPV in High Prev"** — When disease is common, sensitivity drives the negative predictive value. A negative result from a high-sensitivity test reliably excludes disease. In a high-prevalence GDM population: - **Test A (OGTT)** is superior for **screening** — its high sensitivity and NPV mean a negative result confidently excludes GDM, reducing unnecessary confirmatory testing. - **Test B (random glucose)** has better PPV but lower NPV, making it less suitable as a first-line screening tool; it would miss more cases (10% false-negative rate). ### Why NPV is the Best Discriminator The **4.5% absolute difference in NPV** (97.2% vs 92.7%) is the most clinically meaningful distinction between these tests in this population. A negative OGTT result (Test A) is far more reassuring than a negative random glucose result (Test B) when GDM prevalence is high.